Trials / Not Yet Recruiting
Not Yet RecruitingNCT05970627
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Yu jiren · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.
Conditions
- Adenocarcinoma of the Stomach
- Adenocarcinoma of Esophagogastric Junction
- Epstein-Barr Virus-Associated Gastric Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab | Perioperative Toripalimab, 240 mg IV infusion |
| DRUG | Oxaliplatin | Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy |
| DRUG | S1 | S-1 orally intake as perioperative chemotherapy |
Timeline
- Start date
- 2023-07-28
- Primary completion
- 2026-07-28
- Completion
- 2029-07-28
- First posted
- 2023-08-01
- Last updated
- 2023-08-01
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05970627. Inclusion in this directory is not an endorsement.